325 related articles for article (PubMed ID: 30425524)
1. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.
Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M
Onco Targets Ther; 2018; 11():7353-7368. PubMed ID: 30425524
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
3. Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer.
Boudadi K; Antonarakis ES
Clin Med Insights Oncol; 2016; 10(Suppl 1):1-9. PubMed ID: 27013902
[TBL] [Abstract][Full Text] [Related]
4. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
Vander Ark A; Cao J; Li X
Front Oncol; 2018; 8():180. PubMed ID: 29911070
[TBL] [Abstract][Full Text] [Related]
7. Role of Androgen Receptor in Prostate Cancer: A Review.
Fujita K; Nonomura N
World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
9. The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer.
Zheng Z; Li J; Liu Y; Shi Z; Xuan Z; Yang K; Xu C; Bai Y; Fu M; Xiao Q; Sun H; Shao C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230800
[TBL] [Abstract][Full Text] [Related]
10. Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer.
White RE; Bannister M; Day A; Bergom HE; Tan VM; Hwang J; Nguyen HD; Drake JM
bioRxiv; 2023 Apr; ():. PubMed ID: 37163118
[TBL] [Abstract][Full Text] [Related]
11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
12. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.
Alyamani M; Li J; Patel M; Taylor S; Nakamura F; Berk M; Przybycin C; Posadas EM; Madan RA; Gulley JL; Rini B; Garcia JA; Klein EA; Sharifi N
Ann Oncol; 2020 Mar; 31(3):369-376. PubMed ID: 32057540
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer.
Golshayan AR; Antonarakis ES
Core Evid; 2013; 8():27-35. PubMed ID: 23589709
[TBL] [Abstract][Full Text] [Related]
14. Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges.
Kita Y; Goto T; Akamatsu S; Yamasaki T; Inoue T; Ogawa O; Kobayashi T
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30248934
[TBL] [Abstract][Full Text] [Related]
15. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
16. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC.
White RE; Bannister M; Day A; Bergom HE; Tan VM; Hwang J; Dang Nguyen H; Drake JM
Front Oncol; 2023; 13():1210487. PubMed ID: 37456235
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
18. Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance.
Lochrin SE; Figg WD; Finn SP
Cancer Biol Ther; 2015; 16(2):201-3. PubMed ID: 25569176
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
20. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
